KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

AbCellera Biologics (ABCL) Assets Average (2021 - 2026)

AbCellera Biologics filings provide 6 years of Assets Average readings, the most recent being $1.3 billion for Q1 2026.

  • Quarterly Assets Average fell 1.5% to $1.3 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.3 billion through Mar 2026, down 1.5% year-over-year, with the annual reading at $1.4 billion for FY2025, 4.6% down from the prior year.
  • Assets Average hit $1.3 billion in Q1 2026 for AbCellera Biologics, down from $1.4 billion in the prior quarter.
  • Across five years, Assets Average topped out at $1.6 billion in Q2 2022 and bottomed at $1.3 billion in Q1 2026.
  • Average Assets Average over 5 years is $1.5 billion, with a median of $1.5 billion recorded in 2022.
  • The largest annual shift saw Assets Average skyrocketed 39.72% in 2022 before it fell 8.35% in 2025.
  • AbCellera Biologics' Assets Average stood at $1.5 billion in 2022, then fell by 3.01% to $1.5 billion in 2023, then dropped by 8.23% to $1.4 billion in 2024, then dropped by 1.47% to $1.4 billion in 2025, then decreased by 1.8% to $1.3 billion in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Assets Average are $1.3 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.4 billion (Q3 2025).